These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19594756)

  • 1. Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.
    Szczuka A; Wennerberg M; Packeu A; Vauquelin G
    Br J Pharmacol; 2009 Sep; 158(1):183-94. PubMed ID: 19594756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues.
    Bergendal A; Lindén A; Skoogh BE; Gerspacher M; Anderson GP; Löfdahl CG
    Br J Pharmacol; 1996 Mar; 117(6):1009-15. PubMed ID: 8882590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The reassertion profiles of long acting β2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β2-adrenoceptor.
    Patel S; Summerhill S; Stanley M; Perros-Huguet C; Trevethick MA
    Pulm Pharmacol Ther; 2011 Apr; 24(2):247-55. PubMed ID: 21134482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why are long-acting beta-adrenoceptor agonists long-acting?
    Anderson GP; Lindén A; Rabe KF
    Eur Respir J; 1994 Mar; 7(3):569-78. PubMed ID: 7912202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor.
    Green SA; Spasoff AP; Coleman RA; Johnson M; Liggett SB
    J Biol Chem; 1996 Sep; 271(39):24029-35. PubMed ID: 8798639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine.
    Chandramoorthi GD; Piramanayagam S; Marimuthu P
    J Mol Model; 2008 Sep; 14(9):849-56. PubMed ID: 18512086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s).
    Green SA; Rathz DA; Schuster AJ; Liggett SB
    Eur J Pharmacol; 2001 Jun; 421(3):141-7. PubMed ID: 11516429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor.
    January B; Seibold A; Allal C; Whaley BS; Knoll BJ; Moore RH; Dickey BF; Barber R; Clark RB
    Br J Pharmacol; 1998 Feb; 123(4):701-11. PubMed ID: 9517390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol.
    Anderson GP
    Agents Actions Suppl; 1993; 43():253-69. PubMed ID: 8103622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.
    Cooper PR; Kurten RC; Zhang J; Nicholls DJ; Dainty IA; Panettieri RA
    Br J Pharmacol; 2011 Jun; 163(3):521-32. PubMed ID: 21306583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salmeterol, a novel, long-acting beta 2-adrenoceptor agonist: characterization of pharmacological activity in vitro and in vivo.
    Ball DI; Brittain RT; Coleman RA; Denyer LH; Jack D; Johnson M; Lunts LH; Nials AT; Sheldrick KE; Skidmore IF
    Br J Pharmacol; 1991 Nov; 104(3):665-71. PubMed ID: 1686740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salmeterol, a long-acting beta 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line.
    McCrea KE; Hill SJ
    Br J Pharmacol; 1993 Oct; 110(2):619-26. PubMed ID: 7902176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of salmeterol.
    Cazzola M; Testi R; Matera MG
    Clin Pharmacokinet; 2002; 41(1):19-30. PubMed ID: 11825095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.
    Lindén A; Rabe KF; Löfdahl CG
    Lung; 1996; 174(1):1-22. PubMed ID: 8746998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the mechanism of the persistent action of salmeterol: what is the current position?
    Coleman RA
    Br J Pharmacol; 2009 Sep; 158(1):180-2. PubMed ID: 19719780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation.
    Aziz I; McFarlane LC; Lipworth BJ
    Eur J Clin Pharmacol; 1999 Aug; 55(6):431-6. PubMed ID: 10492055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salmeterol.
    Johnson M
    Med Res Rev; 1995 May; 15(3):225-57. PubMed ID: 7658751
    [No Abstract]   [Full Text] [Related]  

  • 18. Investigations into factors determining the duration of action of the beta 2-adrenoceptor agonist, salmeterol.
    Nials AT; Sumner MJ; Johnson M; Coleman RA
    Br J Pharmacol; 1993 Feb; 108(2):507-15. PubMed ID: 8095419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol.
    Grove A; Lipworth BJ
    Thorax; 1996 Jan; 51(1):54-8. PubMed ID: 8658370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An estimation of beta 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators.
    Giembycz MA
    Br J Pharmacol; 2009 Sep; 158(1):287-99. PubMed ID: 19466988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.